XVIVO PERFUSION ABXVIVO PERFUSION ABXVIVO PERFUSION AB

XVIVO PERFUSION AB

No trades
See on Supercharts
Next report date
Report period
EPS estimate
Revenue estimate
Market capitalization
‪14.24 B‬SEK
‪91.82 M‬SEK
‪597.54 M‬SEK
‪24.48 M‬
Beta (1Y)
1.45
Employees (FY)
150
Change (1Y)
+17 +12.78%
Revenue / Employee (1Y)
‪393.18 K‬SEK
Net income / Employee (1Y)
‪60.42 K‬SEK

About XVIVO PERFUSION AB


CEO
Christoffer Rosenblad
Headquarters
Gothenburg
Founded
1998
ISIN
SE0004840718
FIGI
BBG003FHC7K8
Xvivo Perfusion AB is a medical technology company. It involves in developing and marketing solutions and systems for assessing the usability of organs, and maintaining organs in good condition outside the body pending transplantation. Its products include XPS, XPS Disposable Kit, Steen Solution, Organ Chamber, Lung Cannula Set, Perfadex and Silicone Tubing Set. It operates through the Durable Goods and Non-Durable Goods segments. The Durable Goods segment includes sales and rental revenues from machines. The Non-Durable Goods segment covers sales of goods and services that are not durable goods. The company was founded by Magnus Nilsson on December 17, 1998 and is headquartered in Gothenburg, Sweden.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:
‪0.00‬
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of XVIVO is 441.5 SEK — it has decreased by −1.11% in the past 24 hours. Watch XVIVO PERFUSION AB stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on OMXSTO exchange XVIVO PERFUSION AB stocks are traded under the ticker XVIVO.
XVIVO stock has fallen by −1.22% compared to the previous week, the month change is a −11.49% fall, over the last year XVIVO PERFUSION AB has showed a 68.51% increase.
We've gathered analysts' opinions on XVIVO PERFUSION AB future price: according to them, XVIVO price has a max estimate of 575.00 SEK and a min estimate of 480.00 SEK. Watch XVIVO chart and read a more detailed XVIVO PERFUSION AB stock forecast: see what analysts think of XVIVO PERFUSION AB and suggest that you do with its stocks.
XVIVO reached its all-time high on Jul 19, 2024 with the price of 547.0 SEK, and its all-time low was 16.5 SEK and was reached on Feb 19, 2013. View more price dynamics on XVIVO chart.
See other stocks reaching their highest and lowest prices.
XVIVO stock is 2.50% volatile and has beta coefficient of 1.45. Track XVIVO PERFUSION AB stock price on the chart and check out the list of the most volatile stocks — is XVIVO PERFUSION AB there?
Today XVIVO PERFUSION AB has the market capitalization of ‪14.24 B‬, it has increased by 1.46% over the last week.
Yes, you can track XVIVO PERFUSION AB financials in yearly and quarterly reports right on TradingView.
XVIVO PERFUSION AB is going to release the next earnings report on Jan 28, 2025. Keep track of upcoming events with our Earnings Calendar.
XVIVO earnings for the last quarter are 2.80 SEK per share, whereas the estimation was 0.83 SEK resulting in a 237.81% surprise. The estimated earnings for the next quarter are 1.55 SEK per share. See more details about XVIVO PERFUSION AB earnings.
XVIVO PERFUSION AB revenue for the last quarter amounts to ‪198.00 M‬ SEK, despite the estimated figure of ‪205.77 M‬ SEK. In the next quarter, revenue is expected to reach ‪214.55 M‬ SEK.
XVIVO net income for the last quarter is ‪85.82 M‬ SEK, while the quarter before that showed ‪27.19 M‬ SEK of net income which accounts for 215.58% change. Track more XVIVO PERFUSION AB financial stats to get the full picture.
No, XVIVO doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 21, 2024, the company has 150.00 employees. See our rating of the largest employees — is XVIVO PERFUSION AB on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. XVIVO PERFUSION AB EBITDA is ‪134.56 M‬ SEK, and current EBITDA margin is 11.61%. See more stats in XVIVO PERFUSION AB financial statements.
Like other stocks, XVIVO shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade XVIVO PERFUSION AB stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So XVIVO PERFUSION AB technincal analysis shows the sell today, and its 1 week rating is neutral. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating XVIVO PERFUSION AB stock shows the buy signal. See more of XVIVO PERFUSION AB technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.